Φορτώνει......
Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression
BACKGROUND: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that has improved survival and central nervous system (CNS) outcomes in patients with non-small cell lung cancer (NSCLC) with activating EGFR mutations. However, little is known about the efficacy and safety of combin...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Clin Lung Cancer |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2021
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8205932/ https://ncbi.nlm.nih.gov/pubmed/33610453 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2021.01.010 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|